Autism and Cancer Share Risk Genes, Pathways, and Drug Targets

Trends in Genetics

Volumn 32, Issue 3, 2016, Pages 139-146

  Crawley, Jacqueline N ^a,b   Heyer, Wolf Dietrich ^c,d   LaSalle, Janine M ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Cancer; Chromatin remodeling; DNA repair; Gene; Signaling pathway

Indexed keywords

HISTONE METHYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEAR FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR;

ALPHA THALASSEMIA; ARTICLE; AUTISM; CHROMATIN ASSEMBLY AND DISASSEMBLY; COFFIN SIRIS SYNDROME; COSTELLO SYNDROME; DE LANGE SYNDROME; DEVELOPMENTAL DISORDER; DOWN SYNDROME; DRUG TARGETING; EXOME; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOMIC INSTABILITY; HAPPY PUPPET SYNDROME; HELSMOORTEL VAN DER AA SYNDROME; HUMAN; KABUKI MAKEUP SYNDROME; KLEEFSTRA SYNDROME; LENNOX GASTAUT SYNDROME; LONG QT SYNDROME; LONG QT SYNDROME 4; MACROCEPHALY; MACROCEPHALY AUTISM SYNDROME; MENTAL DEFICIENCY; MENTAL DISEASE; MENTAL RETARDATION MALFORMATION SYNDROME; MONOGENIC DISORDER; NEOPLASM; NEUROFIBROMATOSIS; NONHUMAN; NUCLEOSOME; PHELAN-MCDERMID SYNDROME; PRIORITY JOURNAL; RECOMBINATION REPAIR; RETT SYNDROME; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SYNDROME CHARGE; TUBEROUS SCLEROSIS; GENETIC PREDISPOSITION; GENETICS;

AUTISTIC DISORDER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS;

EID: 84958769217     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2016.01.001     Document Type: Short Survey

References (13)

1. Lord C., Bishop S.L. Recent advances in autism research as reflected in DSM-5 criteria for autism spectrum disorder. Annu. Rev. Clin. Psychol. 2015, 11:53-70.
2. Bourgeron T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. 2015, 16:551-563.
3. Iossifov I., et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014, 515:216-221.
4. De Rubeis S., et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014, 515:209-215.
5. Geschwind D.H., State M.W. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol. 2015, 14:1109-1120.
6. Martincorena I., Campbell P.J. Somatic mutation in cancer and normal cells. Science 2015, 349:1483-1489.
7. Zhou J., Parada L.F. PTEN signaling in autism spectrum disorders. Curr. Opin. Neurobiol. 2012, 22:873-879.
8. Pinto D., et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 2014, 94:677-694.
9. Crespi B. Autism and cancer risk. Autism Res. 2011, 4:302-310.
10. LaSalle J.M., et al. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders. Epigenomics 2015, 7:1213-1218.
11. Aguilera A., Garcia-Muse T. Causes of genome instability. Annu. Rev. Genet. 2013, 47:1-32.
12. Chiang H-L., et al. Risk of cancer in children, adolescents, and young adults with autistic disorder. J. Pediatr. 2015, 166:418-423.
13. Kazdoba T.M., et al. Behavioral phenotypes of genetic mouse models of autism. Genes Brain Behav. 2016, 15:7-26.